Clinical Study
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
Figure 1
(a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR ( versus mg/g Cr, ). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.
(a) |
(b) |